세계의 전기 치료/생체 전기 의료 시장 (~2029년) : 심장 박동기, ICD, 인공 와우, 신경 조절 (뇌심부자극)

■ 영문 제목 : Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers, ICD, Cochlear Implant, Neuromodulation (Deep Brain Stimulation)), Type (Implantable, Non-Invasive), Application (Arrhythmia, Heart Failure, Epilepsy) - Global Forecast to 2029

MarketsandMarkets 회사가 출판한 조사자료로, 코드는 MD4358-24 입니다.■ 상품코드 : MD4358-24
■ 조사/발행회사 : MarketsandMarkets
■ 발행일 : 2024년 3월
■ 페이지수 : 382
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : Email (주문후 24시간내 납품)
■ 조사대상 지역 : 글로벌
■ 산업 분야 : 의료
■ 판매가격 / 옵션 (부가세 10% 별도)
Single UserUSD4,950 ⇒환산￦6,930,000견적의뢰/주문/질문
Multi User (Five User)USD6,650 ⇒환산￦9,310,000견적의뢰/주문/질문
Corporate LicenseUSD8,150 ⇒환산￦11,410,000견적의뢰/구입/질문
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
"세계의 전기 치료/생체 전기 의료 시장은 예측 기간 동안 연평균 7.0%의 성장률로 2024년 23.9억 달러에서 2029년 33.6억 달러로 성장할 것으로 예상됩니다." 이러한 성장은 주로 심장 리듬 관리(CRM) 기기에 대한 연구 투자 및 자금 지원 증가, 신경 질환에 대한 정부 지원 및 자금 지원 증가, 신경 질환 및 심혈관 질환의 유병률 증가로 이어지는 노인 인구의 증가 등 여러 요인에 의해 주도되고 있습니다. 그러나 전기 의료 기기의 높은 비용과 막대한 자본 투자가 필요하다는 점이 시장 성장을 저해하고 있습니다.

"예측 기간 동안 제품별 시장에서 가장 높은 성장률을 보인 것은 망막 임플란트 부문입니다."
전기 치료/생체 전기 의료 시장은 제품별로 심장 박동기 및 이식형 제세동기, 신경 조절기, 인공 와우, 망막 임플란트 등으로 구분되며, 2022년에는 망막 임플란트 분야가 전기 제제 시장에서 가장 높은 성장률을 기록할 것으로 예측됩니다. 망막 임플란트의 주요 원동력은 망막색소변성증, 노인성 황반변성 등 망막 퇴행성 질환 환자의 시력을 회복시킬 수 있다는 점입니다.

"비침습적 전기 의료 기기 부문은 예측 기간 동안 가장 높은 수익 성장률을 보일 것으로 예상됩니다."
전기 치료/생체 전기 의료 시장은 이식형 전기 치료기와 비침습적 전기 치료기의 두 가지 세그먼트로 나뉘며, 2022년에는 비침습적 전기 치료기 부문이 가장 높은 성장률을 기록할 것으로 예상됩니다. 이 기기는 외과적 삽입이 필요하지 않으며 전기장이나 자기장을 사용하여 신체 표면의 신경과 근육을 자극합니다. 사용이 간편하고 비용 효율적이며 감염 위험이 낮습니다. 비침습적 전기 치료는 만성 통증, 신경 장애, 대사 장애를 치료하는 데 점점 더 많이 사용되고 있습니다. 비침습적 전기 치료/생체 전기 의료의 기술 발전은 의료비 증가와 만성질환의 유병률 증가와 함께 예측 기간 동안 비침습적 기기 부문의 성장을 촉진할 것으로 예측됩니다.

"아시아 태평양은 전기 치료/생체 전기 의료 시장에서 가장 빠르게 성장하는 지역으로 예상됩니다."
글로벌 전기 치료/생체 전기 의료 시장은 북미, 유럽, 아시아 태평양, 중남미, 중동 및 아프리카로 나뉩니다. 아시아 태평양 지역은 예측 기간 동안 가장 높은 CAGR을 기록할 것으로 예상됩니다. 이러한 성장은 의료비 증가, 의약품 연구비 증가, 질병 조기 발견에 대한 인식을 높이기 위한 정부의 노력, APAC 국가들의 농촌 지역으로의 민간 병원 진출, 이 지역의 고성장 시장 존재 등의 요인에 기인합니다.

본 보고서를 위해 실시한 1차 인터뷰는 다음과 같이 분류됩니다.
- 기업 유형별 : Tier 1 : 28%, Tier 2 : 42%, Tier 3 : 30%.
- 직급별 : C레벨 - 30%, D레벨 - 34%, 기타 - 36%.
- 지역별 : 북미 - 46%, 유럽 - 25%, 아시아 태평양 - 18%, 기타 - 11%.

조사 대상 기업 목록
• Medtronic plc (Ireland)
• Boston Scientific Corporation (US)
• Abbott Laboratories, Inc. (US)
• Cochlear Ltd. (Australia)
• LivaNova PLC (UK)
• MicroPort Scientific Corporation (China)
• Sonova Group (Switzerland)
• Nevro Corp. (US)
• Axonics Modulation Technologies, Inc. (US)
• Neuronetics, Inc. (US)
• ElectroCore, Inc. (US)
• NeuroPace, Inc. (US)
• BIOTRONIK (Germany)
• Medico S.p.A. (Italy)
• Nurotron Biotechnology Co. Ltd. (US)
• MED-EL (Austria)
• Aleva Neurotherapeutics SA (Switzerland)
• NeuroSigma, Inc. (US)
• BioWave Corporation (US)
• Soterix Medical Inc. (US)
• Bioinduction (Amber Therapeutics) (UK)
• GiMer Medical (Taiwan)
• Cefaly (Belgium)
• BioControl Medical (Israel)
• tVNS Technologies GmbH (Germany)

조사 범위
본 보고서는 전기 치료/생체 전기 의료 시장을 제품, 유형, 용도, 지역별로 분류하여 분석 했습니다. 전기 치료/생체 전기 의료 시장의 성장에 영향을 미치는 촉진요인, 저해 요인, 도전 과제, 기회 등 주요 요인에 대한 상세한 정보를 다룹니다. 주요 산업 플레이어를 자세히 분석하여 사업 개요, 솔루션, 주요 전략, 계약, 파트너십, 협정, 신제품 출시, 인수합병, 전기 치료/생체 전기 의료 시장과 관련된 최근 동향에 대한 통찰력을 제공합니다. 이 보고서는 또한 의료용 전해질 시장 생태계에서 떠오르는 신생 기업들에 대한 경쟁 분석도 다루고 있습니다.

보고서 구매의 주요 이점
이 보고서는 전체 전기 치료/생체 전기 의료 시장과 그 하위 부문의 수익에 대한 가장 근접한 추정치를 제공함으로써 시장 리더/신규 진입자에게 도움이 될 것입니다. 또한 이해관계자들이 경쟁 현황을 더 잘 이해하고, 비즈니스 포지셔닝을 개선하고, 적절한 시장 진입 전략을 수립할 수 있는 통찰력을 얻을 수 있도록 돕습니다. 이 보고서는 이해관계자들이 시장의 흐름을 이해하고 주요 시장 촉진 요인, 저해 요인, 도전 과제 및 기회에 대한 정보를 제공할 수 있도록 합니다.

이 보고서는 다음과 같은 사항에 대한 통찰력을 제공합니다.
- 전기 치료/생체 전기 의료 시장의 성장에 영향을 미치는 주요 요인, 저해 요인, 기회, 도전 과제를 분석합니다.
- 제품 개발/혁신 : 시장의 미래 기술, R&D 활동, 신제품 출시에 대한 상세한 통찰력을 제공합니다.
- 시장 개발 : 유리한 시장에 대한 포괄적인 정보 - 이 보고서는 다양한 지역의 전기 제제 시장을 분석합니다.
- 시장 다각화 : 시장 내 신제품, 미개척 지역, 최근 개발 및 투자에 대한 자세한 정보를 제공합니다.
- 경쟁력 평가 : Medtronic plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories, Inc. (US), 및 Cochlear Ltd. (Australia) 등 주요 기업의 시장 순위, 성장 전략 및 제품 제공에 대한 상세한 평가하고 있습니다.
■ 보고서 개요

1 서론
2 조사 방법
3 개요
4 프리미엄 인사이트
5 시장 개요
6 세계의 전기 치료/생체 전기 의료 시장 규모 : 제품별
7 세계의 전기 치료/생체 전기 의료 시장 규모 : 유형별
8 세계의 전기 치료/생체 전기 의료 시장 규모 : 응용 분야별
9 세계의 전기 치료/생체 전기 의료 시장 규모 : 지역별
10 경쟁 현황
11 기업 정보
12 부록

■ 보고서 목차

1 INTRODUCTION 53
1.1 STUDY OBJECTIVES 53
1.2 MARKET DEFINITION 53
1.2.1 INCLUSIONS & EXCLUSIONS OF STUDY 54
1.3 STUDY SCOPE 54
FIGURE 1 ELECTROCEUTICALS MARKET SEGMENTATION 54
1.3.1 GEOGRAPHIC SCOPE 55
1.3.2 YEARS CONSIDERED 55
1.4 CURRENCY 56
1.5 LIMITATIONS 56
1.6 STAKEHOLDERS 56
1.7 SUMMARY OF CHANGES 57
1.7.1 RECESSION IMPACT 57
2 RESEARCH METHODOLOGY 58
2.1 RESEARCH DATA 58
FIGURE 2 RESEARCH DESIGN 58
2.1.1 SECONDARY DATA 59
2.1.1.1 Key data from secondary sources 59
2.1.2 PRIMARY DATA 60
2.1.2.1 Key data from primary sources 61
2.1.2.2 Key industry insights 62
TABLE 1 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 62
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 63
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION 63
2.2 MARKET SIZE ESTIMATION 64
2.2.1 BOTTOM-UP APPROACH 64
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH (COMPANY REVENUE ESTIMATION APPROACH) 64
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH (SEGMENTAL REVENUE ESTIMATION APPROACH) 65
FIGURE 7 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 66
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 66
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 67
FIGURE 9 DATA TRIANGULATION METHODOLOGY 67
2.4 MARKET SHARE ANALYSIS 68
2.5 ASSUMPTIONS 68
2.6 RISK ASSESSMENT 68
TABLE 2 RISK ASSESSMENT: ELECTROCEUTICALS MARKET 68
2.7 LIMITATIONS 69
2.7.1 METHODOLOGY-RELATED LIMITATIONS 69
2.7.2 SCOPE-RELATED LIMITATIONS 69
2.8 IMPACT OF RECESSION ON ELECTROCEUTICALS MARKET 69
3 EXECUTIVE SUMMARY 70
FIGURE 10 ELECTROCEUTICALS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 70
FIGURE 11 ELECTROCEUTICALS MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 71
FIGURE 12 ELECTROCEUTICALS MARKET FOR CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 71
FIGURE 13 ELECTROCEUTICALS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 72
4 PREMIUM INSIGHTS 73
4.1 ELECTROCEUTICALS MARKET OVERVIEW 73
FIGURE 14 RISING PREVALENCE OF NEUROLOGICAL AND CARDIOVASCULAR DISORDERS TO DRIVE MARKET 73
4.2 ELECTROCEUTICALS MARKET SHARE, BY PRODUCT, 2024 VS. 2029 74
FIGURE 15 CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS WILL CONTINUE TO DOMINATE MARKET IN 2029 74
4.3 ELECTROCEUTICALS MARKET SHARE, BY TYPE, 2024 VS. 2029 74
FIGURE 16 IMPLANTABLE ELECTROCEUTICAL DEVICES TO DOMINATE MARKET IN 2024 74
4.4 ELECTROCEUTICALS MARKET SHARE FOR CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY APPLICATION, 2024 VS. 2029 75
FIGURE 17 ARRHYTHMIA SEGMENT TO DOMINATE MARKET IN 2029 75
4.5 ELECTROCEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 75
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN ELECTROCEUTICALS MARKET DURING FORECAST PERIOD 75
5 MARKET OVERVIEW 76
5.1 INTRODUCTION 76
5.2 MARKET DYNAMICS 76
FIGURE 19 ELECTROCEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 76
5.2.1 DRIVERS 77
5.2.1.1 Rising geriatric population and subsequent growth in prevalence of neurological and cardiovascular disorders 77
5.2.1.2 Rising government support and funding for neurological disorders 78
5.2.1.3 Increasing investments and funding for research on CRM devices 78
5.2.1.4 Increasing focus on development of advanced neuromodulation and cardiac devices 79
5.2.1.5 Increasing collaborations among device manufacturers, healthcare providers, and research institutes to develop neuromodulation and cardiac devices 79
5.2.1.6 Availability of reimbursements for neuromodulation, cardiac devices, and cochlear implants 80
5.2.1.7 Growing prevalence of hearing loss and increasing adoption of smart hearing aids 80
5.2.2 RESTRAINTS 81
5.2.2.1 High cost of electroceutical devices 81
5.2.2.2 Preference for drug therapies over neuromodulation and cardiac products 81
5.2.2.3 Adverse effects and complications associated with neuromodulation, cardiac devices, and cochlear implants 81
TABLE 3 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT DEVICES 82
5.2.3 OPPORTUNITIES 82
5.2.3.1 Emerging markets 82
5.2.3.2 Development of ICDs and MRI-compatible ICDs and CRT-Ds 83
5.2.3.3 Integration with digital health platforms 83
5.2.4 CHALLENGES 84
5.2.4.1 Dearth of trained professionals 84
5.2.4.2 Challenges associated with battery life and device replacement 84
5.2.4.3 Complexity and infection issues related to electroceutical devices 85
5.2.5 TRENDS 85
5.2.5.1 Role of artificial intelligence (AI) in electroceutical devices 85
5.2.5.2 Wearable and portable electroceuticals 86
5.3 PRICING ANALYSIS 86
TABLE 4 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT (2022) 86
TABLE 5 AVERAGE SELLING PRICE TREND FOR NEUROMODULATION DEVICES AND PROCEDURES, BY REGION (2022) 86
5.4 VALUE CHAIN ANALYSIS 87
FIGURE 20 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 87
5.5 SUPPLY CHAIN ANALYSIS 88
FIGURE 21 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES 89
5.6 ECOSYSTEM ANALYSIS OF ELECTROCEUTICALS MARKET 89
FIGURE 22 ELECTROCEUTICALS MARKET: ECOSYSTEM ANALYSIS 89
5.6.1 ROLE IN ECOSYSTEM 90
TABLE 6 ELECTROCEUTICALS MARKET: ROLE IN ECOSYSTEM 90
5.6.2 KEY PLAYERS IN ELECTROCEUTICALS MARKET 90
FIGURE 23 ELECTROCEUTICALS MARKET: KEY PLAYERS 90
5.7 PORTER’S FIVE FORCES ANALYSIS 91
TABLE 7 ELECTROCEUTICALS MARKET: PORTER’S FIVE FORCES ANALYSIS 91
5.7.1 THREAT OF NEW ENTRANTS 91
5.7.2 INTENSITY OF COMPETITIVE RIVALRY 91
5.7.3 BARGAINING POWER OF BUYERS 91
5.7.4 BARGAINING POWER OF SUPPLIERS 91
5.7.5 THREAT OF SUBSTITUTES 92
5.8 REGULATORY LANDSCAPE 92
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING ELECTROCEUTICALS MARKET 92
5.8.2 NORTH AMERICA 93
5.8.2.1 US 93
TABLE 9 US FDA: MEDICAL DEVICE CLASSIFICATION 93
TABLE 10 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 93
5.8.2.2 Canada 94
TABLE 11 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 94
5.8.3 EUROPE 94
5.8.4 ASIA PACIFIC 94
5.8.4.1 China 94
TABLE 12 CHINA: CLASSIFICATION OF MEDICAL DEVICES 95
5.8.4.2 Japan 95
5.8.4.3 India 95
5.9 TECHNOLOGY ANALYSIS 96
5.10 TRADE ANALYSIS 97
5.10.1 IMPORT SCENARIO FOR PACEMAKERS 97
TABLE 13 IMPORT DATA FOR PACEMAKERS, BY COUNTRY, 2018–2022 (USD MILLION) 97
5.10.2 EXPORT SCENARIO FOR PACEMAKERS 98
TABLE 14 EXPORT DATA FOR PACEMAKERS, BY COUNTRY, 2018–2022 (USD MILLION) 98
5.10.3 IMPORT SCENARIO FOR COMPLIANT PRODUCTS 98
TABLE 15 IMPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION) 98
5.10.4 EXPORT SCENARIO FOR COMPLIANT PRODUCTS 99
TABLE 16 EXPORT DATA FOR HS CODE 901890-COMPLIANT PRODUCTS, BY COUNTRY, 2018–2022 (USD MILLION) 99
5.11 PATENT ANALYSIS 99
FIGURE 24 ELECTROCEUTICALS MARKET: PATENT ANALYSIS OF CARDIAC PACEMAKERS 99
FIGURE 25 ELECTROCEUTICALS MARKET: PATENT ANALYSIS OF NEUROMODULATION PRODUCTS 100
5.12 KEY CONFERENCES AND EVENTS 100
TABLE 17 LIST OF CONFERENCES & EVENTS, 2024–2025 100
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 102
FIGURE 26 REVENUE SHIFT FOR ELECTROCEUTICALS MARKET 102
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 103
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 103
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 103
5.14.2 BUYING CRITERIA 103
FIGURE 28 KEY BUYING CRITERIA FOR HOSPITALS 103
6 ELECTROCEUTICALS MARKET, BY PRODUCT 104
6.1 INTRODUCTION 105
TABLE 19 ELECTROCEUTICALS MARKET, BY PRODUCT, 2021–2029 (USD MILLION) 105
6.2 CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS 105
6.2.1 INTRODUCTION OF LEADLESS AND MRI-SAFE PACEMAKERS & DEFIBRILLATORS TO BOOST MARKET GROWTH 105
TABLE 20 KEY PRODUCTS IN CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET 107
TABLE 21 CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 108
TABLE 22 NORTH AMERICA: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 108
TABLE 23 EUROPE: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 109
TABLE 24 ASIA PACIFIC: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 109
TABLE 25 MIDDLE EAST & AFRICA: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 110
6.3 COCHLEAR IMPLANTS 110
6.3.1 INCREASING PREVALENCE OF HEARING LOSS TO DRIVE DEMAND 110
TABLE 26 KEY PRODUCTS IN COCHLEAR IMPLANTS MARKET 111
TABLE 27 COCHLEAR IMPLANTS MARKET, BY REGION, 2021–2029 (USD MILLION) 111
TABLE 28 NORTH AMERICA: COCHLEAR IMPLANTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 112
TABLE 29 EUROPE: COCHLEAR IMPLANTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 112
TABLE 30 ASIA PACIFIC: COCHLEAR IMPLANTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 113
TABLE 31 MIDDLE EAST & AFRICA: COCHLEAR IMPLANTS MARKET, BY REGION, 2021–2029 (USD MILLION) 113
6.4 NEUROMODULATORS 113
TABLE 32 NEUROMODULATORS MARKET, BY TYPE, 2021–2029 (USD MILLION) 114
TABLE 33 NEUROMODULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 114
TABLE 34 NORTH AMERICA: NEUROMODULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 115
TABLE 35 EUROPE: NEUROMODULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 115
TABLE 36 ASIA PACIFIC: NEUROMODULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 116
TABLE 37 MIDDLE EAST & AFRICA: NEUROMODULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 116
6.4.1 SPINAL CORD STIMULATORS 116
6.4.1.1 Growing incidence of spinal cord injuries to support market growth 116
TABLE 38 KEY SPINAL CORD STIMULATOR DEVICES AVAILABLE IN MARKET 118
TABLE 39 SPINAL CORD STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 118
TABLE 40 NORTH AMERICA: SPINAL CORD STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 119
TABLE 41 EUROPE: SPINAL CORD STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 119
TABLE 42 ASIA PACIFIC: SPINAL CORD STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 120
TABLE 43 MIDDLE EAST & AFRICA: SPINAL CORD STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 120
6.4.2 DEEP BRAIN STIMULATORS 120
6.4.2.1 Widely used to control debilitating symptoms caused by movement and neurological disorders 120
TABLE 44 KEY DEEP BRAIN STIMULATOR DEVICES AVAILABLE IN MARKET 121
TABLE 45 DEEP BRAIN STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 122
TABLE 46 NORTH AMERICA: DEEP BRAIN STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 122
TABLE 47 EUROPE: DEEP BRAIN STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 123
TABLE 48 ASIA PACIFIC: DEEP BRAIN STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 123
TABLE 49 MIDDLE EAST & AFRICA: DEEP BRAIN STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 124
6.4.3 VAGUS NERVE STIMULATORS 124
6.4.3.1 High incidence of epilepsy to drive market 124
TABLE 50 KEY VAGUS NERVE STIMULATOR DEVICES AVAILABLE IN MARKET 124
TABLE 51 VAGUS NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 125
TABLE 52 NORTH AMERICA: VAGUS NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 125
TABLE 53 EUROPE: VAGUS NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 126
TABLE 54 ASIA PACIFIC: VAGUS NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 126
TABLE 55 MIDDLE EAST & AFRICA: VAGUS NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 127
6.4.4 SACRAL NERVE STIMULATORS 127
6.4.4.1 Widening scope of sacral nerve stimulation to drive growth 127
TABLE 56 KEY SACRAL NERVE STIMULATOR DEVICES AVAILABLE IN MARKET 128
TABLE 57 SACRAL NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 128
TABLE 58 NORTH AMERICA: SACRAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 128
TABLE 59 EUROPE: SACRAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 129
TABLE 60 ASIA PACIFIC: SACRAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 129
TABLE 61 MIDDLE EAST & AFRICA: SACRAL NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 130
6.4.5 GASTRIC ELECTRICAL STIMULATORS 130
6.4.5.1 Growing number of people suffering from severe GERD and gastroparesis to fuel market growth 130
TABLE 62 GASTRIC ELECTRICAL STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 131
TABLE 63 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 131
TABLE 64 EUROPE: GASTRIC ELECTRICAL STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 132
TABLE 65 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 132
TABLE 66 MIDDLE EAST & AFRICA: GASTRIC ELECTRICAL STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 133
6.4.6 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS 133
6.4.6.1 Extensive use in healthcare, low cost, and ease of use to favor market growth 133
TABLE 67 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 134
TABLE 68 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 134
TABLE 69 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 135
TABLE 70 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 135
TABLE 71 MIDDLE EAST & AFRICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 136
6.4.7 TRANSCRANIAL MAGNETIC STIMULATORS 136
6.4.7.1 Minimal patient discomfort associated with TMS to support demand 136
TABLE 72 TRANSCRANIAL MAGNETIC STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 137
TABLE 73 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 137
TABLE 74 EUROPE: TRANSCRANIAL MAGNETIC STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 138
TABLE 75 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 138
TABLE 76 MIDDLE EAST & AFRICA: TRANSCRANIAL MAGNETIC STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 139
6.4.8 RESPIRATORY ELECTRICAL STIMULATORS 139
6.4.8.1 Increasing incidence of spinal cord injuries to drive market 139
TABLE 77 RESPIRATORY ELECTRICAL STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 140
TABLE 78 NORTH AMERICA: RESPIRATORY ELECTRICAL STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 140
TABLE 79 EUROPE: RESPIRATORY ELECTRICAL STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 141
TABLE 80 ASIA PACIFIC: RESPIRATORY ELECTRICAL STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 141
TABLE 81 MIDDLE EAST & AFRICA: RESPIRATORY ELECTRICAL STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 142
6.4.9 TRIGEMINAL NERVE STIMULATORS 142
6.4.9.1 High treatment efficacy to fuel market growth 142
TABLE 82 TRIGEMINAL NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 142
TABLE 83 NORTH AMERICA: TRIGEMINAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 143
TABLE 84 EUROPE: TRIGEMINAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 143
TABLE 85 ASIA PACIFIC: TRIGEMINAL NERVE STIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 144
TABLE 86 MIDDLE EAST & AFRICA: TRIGEMINAL NERVE STIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 144
6.4.10 RESPONSIVE NEUROSTIMULATORS 144
6.4.10.1 Targeted and personalized treatment to fuel market growth 144
TABLE 87 RESPONSIVE NEUROSTIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 145
TABLE 88 NORTH AMERICA: RESPONSIVE NEUROSTIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 145
TABLE 89 EUROPE: RESPONSIVE NEUROSTIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 146
TABLE 90 ASIA PACIFIC: RESPONSIVE NEUROSTIMULATORS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 146
TABLE 91 MIDDLE EAST & AFRICA: RESPONSIVE NEUROSTIMULATORS MARKET, BY REGION, 2021–2029 (USD MILLION) 147
6.5 RETINAL IMPLANTS 147
6.5.1 GROWING NUMBER OF RETINITIS PIGMENTOSA CASES TO SUPPORT MARKET GROWTH 147
TABLE 92 RETINAL IMPLANTS MARKET, BY REGION, 2021–2029 (USD MILLION) 148
TABLE 93 NORTH AMERICA: RETINAL IMPLANTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 148
TABLE 94 EUROPE: RETINAL IMPLANTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 149
TABLE 95 ASIA PACIFIC: RETINAL IMPLANTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 149
TABLE 96 MIDDLE EAST & AFRICA: RETINAL IMPLANTS MARKET, BY REGION, 2021–2029 (USD MILLION) 150
7 ELECTROCEUTICALS MARKET, BY TYPE 151
7.1 INTRODUCTION 152
TABLE 97 ELECTROCEUTICALS MARKET, BY TYPE, 2021–2029 (USD MILLION) 152
7.2 IMPLANTABLE ELECTROCEUTICAL DEVICES 152
7.2.1 LONG-TERM COST SAVINGS TO DRIVE MARKET 152
TABLE 98 IMPLANTABLE ELECTROCEUTICAL DEVICES MARKET, BY REGION, 2021–2029 (USD MILLION) 154
TABLE 99 NORTH AMERICA: IMPLANTABLE ELECTROCEUTICAL DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 154
TABLE 100 EUROPE: IMPLANTABLE ELECTROCEUTICAL DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 155
TABLE 101 ASIA PACIFIC: IMPLANTABLE ELECTROCEUTICAL DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 155
TABLE 102 MIDDLE EAST & AFRICA: IMPLANTABLE ELECTROCEUTICAL DEVICES MARKET, BY REGION, 2021–2029 (USD MILLION) 156
7.3 NONINVASIVE ELECTROCEUTICAL DEVICES 156
7.3.1 EXTENSIVE USE IN HEALTHCARE, EASE OF USE, AND LOW COST TO SUPPORT MARKET GROWTH 156
TABLE 103 NONINVASIVE ELECTROCEUTICAL DEVICES MARKET, BY REGION, 2021–2029 (USD MILLION) 157
TABLE 104 NORTH AMERICA: NONINVASIVE ELECTROCEUTICAL DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 158
TABLE 105 EUROPE: NONINVASIVE ELECTROCEUTICAL DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 158
TABLE 106 ASIA PACIFIC: NONINVASIVE ELECTROCEUTICAL DEVICES MARKET, BY COUNTRY, 2021–2029 (USD MILLION) 159
TABLE 107 MIDDLE EAST & AFRICA: NONINVASIVE ELECTROCEUTICAL DEVICES MARKET, BY REGION, 2021–2029 (USD MILLION) 159
8 ELECTROCEUTICALS MARKET, BY APPLICATION 160
8.1 INTRODUCTION 161
8.2 ELECTROCEUTICALS MARKET FOR CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD), BY APPLICATION 161
TABLE 108 ELECTROCEUTICALS MARKET FOR CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS, BY APPLICATION, 2021–2029 (USD MILLION) 161
8.2.1 ARRHYTHMIA 161
8.2.1.1 Increasing prevalence of arrhythmia to support market growth 161
TABLE 109 CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR ARRHYTHMIA, BY REGION, 2021–2029 (USD MILLION) 162
TABLE 110 NORTH AMERICA: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR ARRHYTHMIA, BY COUNTRY, 2021–2029 (USD MILLION) 162
TABLE 111 EUROPE: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR ARRHYTHMIA, BY COUNTRY, 2021–2029 (USD MILLION) 163
TABLE 112 ASIA PACIFIC: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR ARRHYTHMIA, BY COUNTRY, 2021–2029 (USD MILLION) 163
8.2.2 HEART FAILURE 164
8.2.2.1 Rising prevalence of heart-related conditions in older individuals to drive growth 164
TABLE 113 CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR HEART FAILURE, BY REGION, 2021–2029 (USD MILLION) 164
TABLE 114 NORTH AMERICA: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR HEART FAILURE, BY COUNTRY, 2021–2029 (USD MILLION) 165
TABLE 115 EUROPE: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR HEART FAILURE, BY COUNTRY, 2021–2029 (USD MILLION) 165
TABLE 116 ASIA PACIFIC: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR HEART FAILURE, BY COUNTRY, 2021–2029 (USD MILLION) 166
8.2.3 OTHER CARDIAC PACEMAKER & ICD APPLICATIONS 166
TABLE 117 CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2029 (USD MILLION) 167
TABLE 118 NORTH AMERICA: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 167
TABLE 119 EUROPE: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 168
TABLE 120 ASIA PACIFIC: CARDIAC PACEMAKERS & IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 168
8.3 ELECTROCEUTICALS MARKET FOR SPINAL CORD STIMULATORS, BY APPLICATION 169
TABLE 121 ELECTROCEUTICALS MARKET FOR SPINAL CORD STIMULATORS, BY APPLICATION, 2021–2029 (USD MILLION) 169
8.3.1 CHRONIC PAIN 169
8.3.1.1 High incidence of chronic pain to support market growth 169
TABLE 122 SPINAL CORD STIMULATORS MARKET FOR CHRONIC PAIN, BY REGION, 2021–2029 (USD MILLION) 170
TABLE 123 NORTH AMERICA: SPINAL CORD STIMULATORS MARKET FOR CHRONIC PAIN, BY COUNTRY, 2021–2029 (USD MILLION) 170
TABLE 124 EUROPE: SPINAL CORD STIMULATORS MARKET FOR CHRONIC PAIN, BY COUNTRY, 2021–2029 (USD MILLION) 171
TABLE 125 ASIA PACIFIC: SPINAL CORD STIMULATORS MARKET FOR CHRONIC PAIN, BY COUNTRY, 2021–2029 (USD MILLION) 171
8.3.2 FAILED BACK SURGERY SYNDROME 172
8.3.2.1 Increasing incidence of FBSS to drive demand 172
TABLE 126 SPINAL CORD STIMULATORS MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2021–2029 (USD MILLION) 172
TABLE 127 NORTH AMERICA: SPINAL CORD STIMULATORS MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2021–2029 (USD MILLION) 173
TABLE 128 EUROPE: SPINAL CORD STIMULATORS MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2021–2029 (USD MILLION) 173
TABLE 129 ASIA PACIFIC: SPINAL CORD STIMULATORS MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2021–2029 (USD MILLION) 174
8.3.3 ISCHEMIA 174
8.3.3.1 High effectiveness of neuromodulation for ischemia treatment to propel market 174
TABLE 130 SPINAL CORD STIMULATORS MARKET FOR ISCHEMIA, BY REGION, 2021–2029 (USD MILLION) 175
TABLE 131 NORTH AMERICA: SPINAL CORD STIMULATORS MARKET FOR ISCHEMIA, BY COUNTRY, 2021–2029 (USD MILLION) 175
TABLE 132 EUROPE: SPINAL CORD STIMULATORS MARKET FOR ISCHEMIA, BY COUNTRY, 2021–2029 (USD MILLION) 176
TABLE 133 ASIA PACIFIC: SPINAL CORD STIMULATORS MARKET FOR ISCHEMIA, BY COUNTRY, 2021–2029 (USD MILLION) 176
8.4 ELECTROCEUTICALS MARKET FOR DEEP BRAIN STIMULATORS, BY APPLICATION 177
TABLE 134 ELECTROCEUTICALS MARKET FOR DEEP BRAIN STIMULATORS, BY APPLICATION, 2021–2029 (USD MILLION) 177
8.4.1 PARKINSON’S DISEASE 177
8.4.1.1 Rising incidence of Parkinson’s disease and growing R&D to drive market 177
TABLE 135 DEEP BRAIN STIMULATORS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021–2029 (USD MILLION) 178
TABLE 136 NORTH AMERICA: DEEP BRAIN STIMULATORS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2021–2029 (USD MILLION) 178
TABLE 137 EUROPE: DEEP BRAIN STIMULATORS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2021–2029 (USD MILLION) 179
TABLE 138 ASIA PACIFIC: DEEP BRAIN STIMULATORS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2021–2029 (USD MILLION) 179
8.4.2 TREMORS 180
8.4.2.1 High efficacy of DBS in treating tremors to drive market 180
TABLE 139 DEEP BRAIN STIMULATORS MARKET FOR TREMORS, BY REGION, 2021–2029 (USD MILLION) 180
TABLE 140 NORTH AMERICA: DEEP BRAIN STIMULATORS MARKET FOR TREMORS, BY COUNTRY, 2021–2029 (USD MILLION) 180
TABLE 141 EUROPE: DEEP BRAIN STIMULATORS MARKET FOR TREMORS, BY COUNTRY, 2021–2029 (USD MILLION) 181
TABLE 142 ASIA PACIFIC: DEEP BRAIN STIMULATORS MARKET FOR TREMORS, BY COUNTRY, 2021–2029 (USD MILLION) 181
8.4.3 DEPRESSION 182
8.4.3.1 Rising research and clinical studies related to depression treatment to propel market 182
TABLE 143 DEEP BRAIN STIMULATORS MARKET FOR DEPRESSION, BY REGION, 2021–2029 (USD MILLION) 182
TABLE 144 NORTH AMERICA: DEEP BRAIN STIMULATORS MARKET FOR DEPRESSION, BY COUNTRY, 2021–2029 (USD MILLION) 183
TABLE 145 EUROPE: DEEP BRAIN STIMULATORS MARKET FOR DEPRESSION, BY COUNTRY, 2021–2029 (USD MILLION) 183
TABLE 146 ASIA PACIFIC: DEEP BRAIN STIMULATORS MARKET FOR DEPRESSION, BY COUNTRY, 2021–2029 (USD MILLION) 184
8.4.4 OTHER DBS APPLICATIONS 184
TABLE 147 DEEP BRAIN STIMULATORS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2029 (USD MILLION) 185
TABLE 148 NORTH AMERICA: DEEP BRAIN STIMULATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 185
TABLE 149 EUROPE: DEEP BRAIN STIMULATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 186
TABLE 150 ASIA PACIFIC: DEEP BRAIN STIMULATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 186
8.5 ELECTROCEUTICALS MARKET FOR SACRAL NERVE STIMULATORS, BY APPLICATION 187
TABLE 151 ELECTROCEUTICALS MARKET FOR SACRAL NERVE STIMULATORS, BY APPLICATION, 2021–2029 (USD MILLION) 187
8.5.1 URINE INCONTINENCE 187
8.5.1.1 High incidence of urine incontinence to offer growth opportunities for market players 187
TABLE 152 SACRAL NERVE STIMULATORS MARKET FOR URINE INCONTINENCE, BY REGION, 2021–2029 (USD MILLION) 188
TABLE 153 NORTH AMERICA: SACRAL NERVE STIMULATORS MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2021–2029 (USD MILLION) 188
TABLE 154 EUROPE: SACRAL NERVE STIMULATORS MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2021–2029 (USD MILLION) 189
TABLE 155 ASIA PACIFIC: SACRAL NERVE STIMULATORS MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2021–2029 (USD MILLION) 189
8.5.2 FECAL INCONTINENCE 190
8.5.2.1 Reduced symptom recurrence with use of SNS to drive demand 190
TABLE 156 SACRAL NERVE STIMULATORS MARKET FOR FECAL INCONTINENCE, BY REGION, 2021–2029 (USD MILLION) 190
TABLE 157 NORTH AMERICA: SACRAL NERVE STIMULATORS MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2021–2029 (USD MILLION) 190
TABLE 158 EUROPE: SACRAL NERVE STIMULATORS MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2021–2029 (USD MILLION) 191
TABLE 159 ASIA PACIFIC: SACRAL NERVE STIMULATORS MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2021–2029 (USD MILLION) 191
8.6 ELECTROCEUTICALS MARKET FOR VAGUS NERVE STIMULATORS, BY APPLICATION 192
TABLE 160 ELECTROCEUTICALS MARKET FOR VAGUS NERVE SIMULATORS, BY APPLICATION, 2021–2029 (USD MILLION) 192
8.6.1 EPILEPSY 192
8.6.1.1 Advantages associated with VNS in epilepsy treatment to propel market 192
TABLE 161 VAGUS NERVE STIMULATORS MARKET FOR EPILEPSY, BY REGION, 2021–2029 (USD MILLION) 192
TABLE 162 NORTH AMERICA: VAGUS NERVE STIMULATORS MARKET FOR EPILEPSY, BY COUNTRY, 2021–2029 (USD MILLION) 193
TABLE 163 EUROPE: VAGUS NERVE STIMULATORS MARKET FOR EPILEPSY, BY COUNTRY, 2021–2029 (USD MILLION) 193
TABLE 164 ASIA PACIFIC: VAGUS NERVE STIMULATORS MARKET FOR EPILEPSY, BY COUNTRY, 2021–2029 (USD MILLION) 194
8.6.2 OTHER VNS APPLICATIONS 194
TABLE 165 VAGUS NERVE STIMULATORS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2029 (USD MILLION) 194
TABLE 166 NORTH AMERICA: VAGUS NERVE STIMULATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 195
TABLE 167 EUROPE: VAGUS NERVE STIMULATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 195
TABLE 168 ASIA PACIFIC: VAGUS NERVE STIMULATORS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2029 (USD MILLION) 196
8.7 ELECTROCEUTICALS MARKET FOR GASTRIC ELECTRICAL STIMULATORS, BY APPLICATION 196
TABLE 169 ELECTROCEUTICALS MARKET FOR GASTRIC ELECTRICAL STIMULATORS, BY APPLICATION, 2021–2029 (USD MILLION) 196
8.7.1 GASTROPARESIS 197
8.7.1.1 Reduced hospitalization time associated with GES treatment to drive market 197
TABLE 170 GASTRIC ELECTRICAL STIMULATORS MARKET FOR GASTROPARESIS, BY REGION, 2021–2029 (USD MILLION) 197
TABLE 171 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATORS MARKET FOR GASTROPARESIS, BY COUNTRY, 2021–2029 (USD MILLION) 197
TABLE 172 EUROPE: GASTRIC ELECTRICAL STIMULATORS MARKET FOR GASTROPARESIS, BY COUNTRY, 2021–2029 (USD MILLION) 198
TABLE 173 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATORS MARKET FOR GASTROPARESIS, BY COUNTRY, 2021–2029 (USD MILLION) 198
8.7.2 OBESITY 199
8.7.2.1 High prevalence of obesity and risks associated with gastric bypass to propel market 199
TABLE 174 GASTRIC ELECTRICAL STIMULATORS MARKET FOR OBESITY, BY REGION, 2021–2029 (USD MILLION) 199
TABLE 175 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATORS MARKET FOR OBESITY, BY COUNTRY, 2021–2029 (USD MILLION) 199
TABLE 176 EUROPE: GASTRIC ELECTRICAL STIMULATORS MARKET FOR OBESITY, BY COUNTRY, 2021–2029 (USD MILLION) 200
TABLE 177 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATORS MARKET FOR OBESITY, BY COUNTRY, 2021–2029 (USD MILLION) 200

보고서 이미지

※본 조사보고서 [세계의 전기 치료/생체 전기 의료 시장 (~2029년) : 심장 박동기, ICD, 인공 와우, 신경 조절 (뇌심부자극)] (코드 : MD4358-24) 판매에 관한 면책사항을 반드시 확인하세요.
※본 조사보고서 [세계의 전기 치료/생체 전기 의료 시장 (~2029년) : 심장 박동기, ICD, 인공 와우, 신경 조절 (뇌심부자극)] 에 대해서 E메일 문의는 여기를 클릭하세요.
*** 아래는 관련 보고서 소개입니다 ***

  • 세계의 의료 기기 수탁 제조 시장 (~2027년)
    MD7111-23 / MarketsandMarkets / 2023년 1월 / 마켓츠앤마켓츠 (MarketsandMarkets)는 세계의 의료 기기 수탁 제조 시장 규모가 2022년 712억 달러에서 2027년 1,189억 달러에 이르며, 예측 기간 동안 연평균 10.8%로 성장할 것으로 예측하고 있습니다. 본 조사 리포트는 세계의 의료...“The global medical device contract manufacturing market is projected to reach USD 118.9 billion in 2027 from USD 71.2 billion in 2022, at a CAGR of 10.8%.”The rapid advancements in technology related to medical devices and automation of manufacturing are factors driving the market. Additionally, increasing expenditure on healthcare infrastructure...
  • 세계의 엑소좀 연구 시장 (~2028년) : 키트, 시약 (항체, 분리 정제), 기기
    BT6939-24 / MarketsandMarkets / 2024년 1월 / "글로벌 엑소좀 연구 시장은 2023년 약 1억 6900만 달러에서 2028년 35억 6000만 달러에 달할 것으로 예상되며, 예측 기간 동안 16.0%의 CAGR을 기록할 것으로 전망됩니다." 이 시장의 성장은 암, 신경 퇴행성...1. 서론 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 엑소좀 연구 시장 규모 : 제품 및 서비스별 7. 세계의 엑소좀 연구 시장 규모 : 질환별 8. 세계의 엑소좀 연구 시장 규모 : 용도별 9. 세계의 엑소좀 연구 시장 규모 : 최종 용도별 10. 세계의...
  • 세계의 생물제제 안전성 시험 시장 (~2029년) : 제품 및 서비스별 (소모품, 장비, 서비스), 검사 유형별 (마이코플라즈마, 무균성, 내독소, 바이오바덴, 바이러스 안전성), 용도별 (백신, mAb, 세포 및 유전자 치료, 혈액 제제)
    BT3334 / MarketsandMarkets / 2024년 5월 / ...“세계의 생물제제 안전성 시험 시장은 2024년 42억 달러에서 2029년에는 72억 달러에 달할 것으로 예상되며, 2024년부터 2029년까지 11.1%의 연평균 성장률을 기록할 것으로 전망됩니다.”이 시장의 성장은 새로운 생물학적 제제의 개발 및 제조에 대한 관심이 높아진 데 기인합니다. 만성 질환의 증가로 인해 세포 및 유전자 치료와 같은 첨단 치료법에 대한 수요가 증가함에 따라...
  • 세계의 병리학 AI 시장 (~2029년) : 신경망별 (GAN, CNN, RNN), 기능별 (진단, 영상 분석, CDSS, 데이터 관리, 분석), 사용 사례별 (신약 개발, 임상 워크플로우), 최종 사용자별 (병원, 연구소, 제약/바이오테크), 지역별
    HIT 8721 / MarketsandMarkets / 2024년 11월 / ...“세계 병리학 AI 시장은 예측 기간 동안 15.4%의 높은 CAGR로 2024년 8,280만 달러에서 2029년에는 1억 6,980만 달러에 이를 것으로 전망” 병리학 AI는 특히 병리학 애플리케이션용으로 설계된 인공지능(AI)의 개발, 배치, 활용으로 구성된 헬스케어 산업 분야를 말합니다. 임상 데이터, 게놈 정보, 질병의 진행은 이러한 AI 모델을 사용하여 분석할 수 있습니다. 이러한 AI...
  • 세계의 단백질 발현 시장 (~2029년) : 제품별 (시약, 벡터, 유능한 세포, 장치, 소프트웨어), 서비스별, 시스템 종류별 (포유류 (CHO, HEK293), 곤충, 효모), 워크플로별, 용도별 (치료, 연구, 산업)
    BT 2435 / MarketsandMarkets / 2024년 11월 / ...“세계 단백질 발현 시장은 2029년에 48.2억 달러에 이를 것으로 예상되며, 2024년에는 34.1억 달러에서 예측 기간 중 CAGR은 7.1%” 제약 및 바이오 의약품 업계의 연구개발 활동 증가에 힘입은 생물 제제의 수요 증가와 단백질 기반 연구를 강화하기 위한 인공지능 및 기계 학습의 이용 확대와 같은 요인이 시장 성장을 뒷받침하고 있습니다. 또한 개별화...

    • ※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!